Nurix Therapeutics (NASDAQ:NRIX) Insider Gwenn Hansen Sells 1,452 Shares of Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) insider Gwenn Hansen sold 1,452 shares of the business’s stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $25.47, for a total value of $36,982.44. Following the completion of the sale, the insider directly owned 117,227 shares in the company, valued at approximately $2,985,771.69. This represents a 1.22% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Gwenn Hansen also recently made the following trade(s):

• On Wednesday, August 5th, Gwenn Hansen sold 4,356 shares of Nurix Therapeutics stock. The stock was sold at an average price of $25.00, for a total value of $108,900.00.
• On Tuesday, August 4th, Gwenn Hansen sold 4,111 shares of Nurix Therapeutics stock. The shares were sold at an average price of $24.36, for a total value of $100,143.96.
• On Thursday, July 30th, Gwenn Hansen sold 3,847 shares of Nurix Therapeutics stock. The shares were sold at an average price of $23.38, for a total transaction of $89,942.86.
• On Thursday, June 25th, Gwenn Hansen sold 5,394 shares of Nurix Therapeutics stock. The shares were sold at an average price of $20.00, for a total transaction of $107,880.00.

Nurix Therapeutics Price Performance

Shares of NRIX traded up $0.26 during trading hours on Tuesday, hitting $26.04. The stock had a trading volume of 1,323,331 shares, compared to its average volume of 1,456,768. The stock has a market capitalization of $2.70 billion, a price-to-earnings ratio of -7.55 and a beta of 1.79. The company’s fifty day moving average is $24.51 and its two-hundred day moving average is $19.07. Nurix Therapeutics, Inc. has a 52 week low of $8.19 and a 52 week high of $28.23.

Nurix Therapeutics (NASDAQ:NRIX) last announced its quarterly earnings results on Thursday, July 9th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.73) by ($0.08). The firm had revenue of $9.04 million for the quarter, compared to the consensus estimate of $15.29 million. Nurix Therapeutics had a negative net margin of 928.44% and a negative return on equity of 76.09%. Equities analysts predict that Nurix Therapeutics, Inc. will post -2.73 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in NRIX. Nykredit A S bought a new stake in Nurix Therapeutics in the second quarter valued at about $32,000. Larson Financial Group LLC raised its holdings in Nurix Therapeutics by 339.0% during the 4th quarter. Larson Financial Group LLC now owns 1,541 shares of the company’s stock worth $29,000 after buying an additional 1,190 shares during the period. Intesa Sanpaolo Wealth Management bought a new stake in shares of Nurix Therapeutics during the fourth quarter worth $31,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of Nurix Therapeutics during the fourth quarter worth $33,000. Finally, KBC Group NV acquired a new stake in shares of Nurix Therapeutics during the first quarter worth $34,000.

Wall Street Analyst Weigh In

NRIX has been the subject of a number of research analyst reports. Mizuho lifted their target price on shares of Nurix Therapeutics from $30.00 to $34.00 and gave the company an “outperform” rating in a research note on Monday, July 13th. Royal Bank Of Canada increased their price target on Nurix Therapeutics from $33.00 to $36.00 and gave the stock an “outperform” rating in a research report on Monday, August 10th. Jefferies Financial Group raised their price target on Nurix Therapeutics from $41.00 to $45.00 and gave the company a “buy” rating in a report on Monday, June 8th. Truist Financial lifted their price objective on Nurix Therapeutics from $32.00 to $34.00 and gave the company a “buy” rating in a research report on Friday, July 10th. Finally, Stifel Nicolaus boosted their price objective on Nurix Therapeutics from $34.00 to $40.00 and gave the stock a “buy” rating in a research note on Friday, July 10th. Thirteen research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $34.21.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.